[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Article
December 15, 2008

Roux-en-Y Reconstruction After Pancreaticoduodenectomy

Author Affiliations

Author Affiliations: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. Dr Grobmyer is now with the Division of Surgical Oncology, Department of Surgery, University of Florida, Gainesville.

Arch Surg. 2008;143(12):1184-1188. doi:10.1001/archsurg.2008.501

Hypothesis  Roux-en-Y reconstruction (RYR) is associated with a reduction in morbidity and mortality associated with pancreatic anastomotic failure after pancreaticoduodenectomy compared with conventional loop reconstruction (CLR).

Design  Retrospective study of patients from 1991 to 2006.

Setting  Tertiary care center.

Patients  Records of patients undergoing CLR (n = 588) and patients undergoing RYR (n = 112) between February 1, 1991, and June 30, 2006, for pancreatic ductal adenocarcinoma at a single institution were retrospectively reviewed and compared.

Main Outcome Measures  Perioperative outcome and mortality were compared for patients who underwent RYR compared with those who underwent CLR.

Results  Overall, both groups required a similar rate of postoperative interventional radiology procedures (CLR, 6.8%; RYR, 9.8%; P = .24) and subsequent operations (CLR, 6.9%; RYR, 9.1%; P = .62). No significant difference was found in the rate of overall postoperative mortality (CLR, 2.6%; RYR, 0.9%; P = .49). The overall rate of pancreatic anastomotic failure was 7.2%, and pancreatic anastomotic failure was associated with a 6% mortality rate. Among patients who developed pancreatic anastomotic failure, no significant difference was seen between CLR (n = 32) and RYR (n = 16) in length of hospital stay (18 vs 19 days; P = .98) or postoperative mortality (3 patients [9.4%] vs none [0%]; P = .54).

Conclusion  We found that RYR is not associated with a reduction in morbidity after pancreaticoduodenectomy for pancreatic adenocarcinoma compared with CLR, even among patients who develop pancreatic anastomotic failure.